Today: 8 February 2026
Subscribe
Browse Category

NYSE:SNY News 16 September 2025 - 17 January 2026

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck & Co shares fell 1.9% to $108.83 Friday after a Reuters report highlighted industry concerns over the FDA’s new fast-track drug approval program. Internal FDA documents show some drug reviews have been delayed due to safety and effectiveness worries, including a patient death linked to Sanofi’s Tzield. The S&P 500 healthcare sector dropped 0.8% amid broader market weakness. Only one drug has been approved under the program so far.
17 January 2026
·····
Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer shares rose 0.3% to $25.67 Thursday as investors weighed U.S. vaccine policy debates and the company’s growth outlook. The stock moved between $25.26 and $25.67 with 22.3 million shares traded. Pfizer will report Q4 results on Feb. 3, with guidance projecting 2026 revenue of $59.5–$62.5 billion and lower COVID-19 product sales. Competition in obesity drugs and AI-driven drug discovery remain in focus.
15 January 2026
····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Sanofi agreed to acquire Dynavax Technologies for $15.50 per share in cash, valuing the deal at about $2.2 billion. DVAX shares surged 39% to around $15.45, trading near the offer price after the announcement. Volume topped 30 million shares in a volatile session shortened for the holiday. The transaction is expected to close in Q1 2026, pending customary conditions.
24 December 2025
··
Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Sanofi announced a deal to acquire Dynavax Technologies for $2.2 billion in cash, offering $15.50 per share—a 39% premium to Dynavax’s prior close. DVAX stock jumped about 37% premarket to near the offer price. Dynavax’s board approved the transaction. Closing is expected in Q1 2026, pending regulatory and shareholder approvals.
24 December 2025
···
EU Stock Markets Today (24 December 2025): STOXX 600 Flat on Christmas Eve as BP Castrol Deal, Sanofi’s Dynavax Move and Record Metals Set the Tone

EU Stock Markets Today (24 December 2025): STOXX 600 Flat on Christmas Eve as BP Castrol Deal, Sanofi’s Dynavax Move and Record Metals Set the Tone

The STOXX 600 index was flat at 588.93 by 08:09 GMT on December 24, 2025, as EU stock markets saw sharply reduced liquidity with Germany and Italy closed and other exchanges running shortened sessions for Christmas Eve. Energy shares rose on firmer oil, while miners tracked gains in precious metals. Trading volumes were thin across the continent.
24 December 2025
···
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Richmond’s New Pharma Giant: Overview of Lilly’s $5B Factory Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction Washingtonpost. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil Washingtonpost Washingtonpost. Scale and Scope: The plant will
16 September 2025
·······

Stock Market Today

RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

8 February 2026
RELX shares fell 4.6% to 2,145p on Friday, near a 52-week low, despite the FTSE 100 closing higher. The company disclosed a new buyback of 465,361 shares on Feb. 6 and has repurchased over 8.8 million shares since Jan. 2. Investors await RELX’s full-year 2025 results on Feb. 12 amid concerns over AI’s impact on its core business.
Glencore shares steady after Rio walks away — what to watch before Monday’s trade

Glencore shares steady after Rio walks away — what to watch before Monday’s trade

8 February 2026
Glencore shares closed up 0.6% at 478.10 pence Friday after Rio Tinto ended merger talks, issuing a “no intention to bid” statement. Glencore’s board rejected the proposed deal terms, citing concerns over valuation and governance. Attention now turns to possible asset sales, including its $5 billion Kazzinc stake, ahead of Glencore’s annual results on Feb. 18.
Go toTop